The Most Affordable CAR-T Biotech Stock Among Its Rivals Right Now


Juno Therapeutics is now the "cheapest" player now developing CAR-T cancer medications, an analyst said Wednesday as he downgraded rival bluebird bio.

Both are working on CAR-T therapies in which a patient's immune cells are extracted, taught to fight cancer and then reintroduced to the body. Juno and Bluebird each had strong data during the American Society of Hematology conference in Atlanta.

Back to news